

Wellnex Life Limited (ASX:WNX) Update on Pain Away Transaction

Wellnex Life Limited (ASX:WNX) ("**Wellnex**" or "**Company**") provides an update regarding the acquisition of Pain Away, as announced to the ASX on 25 May 2023 and 1 August 2023. Parties have mutually agreed to further extend the deadline of completion to 30 September 2023 whilst parties are negotiating revised terms. The negotiations are at the final stage and the Company expects to announce the revised terms by no later than Friday, 8 September 2023.

In addition, as previously announced, Wellnex is in the process of completing the shortfall offer under the pro-rata non-renounceable entitlement offer (see ASX announcements dated 25 July 2023 and 1 August 2023) (**Shortfall Offer**).

The Company expects the voluntary suspension to be lifted following completion of the Pain Away transaction.

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

Media & Investor Enquiries

The Capital Network

Julia Maguire

P: +61 2 8999 3699

E: julia@thecapitalnetwork.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/